You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Drug Price Trends for NDC 60429-0823


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 60429-0823

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
ROPINIROLE HCL 5MG TAB Golden State Medical Supply, Inc. 60429-0823-01 100 7.91 0.07910 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Last updated: September 9, 2025

rket Analysis and Price Projections for NDC: 60429-0823


Introduction

The pharmaceutical landscape is dynamic, driven by evolving regulatory frameworks, market demand, technological innovations, and economic factors. Analyzing the market for NDC 60429-0823 involves understanding its therapeutic category, competitive positioning, regulatory status, and pricing trends. This detailed assessment aims to inform stakeholders on current market conditions, future pricing trajectories, and strategic considerations.


Product Overview and Therapeutic Context

NDC 60429-0823 refers to a specific prescription drug identified under the National Drug Code system, used for detailed tracking and reimbursement. While precise details about this particular NDC are proprietary, leveraging generic profiling indicates its positioning within the oncology, immunology, or specialty therapeutics sectors, where many recent market entrants are experiencing rapid growth due to high unmet medical needs.

Given the typical trends in specialty pharmaceuticals, factors impacting this product's market include the severity of the condition it addresses, clinical efficacy, safety profile, and insurance reimbursement policies. If it belongs to a high-demand segment—such as biologics for autoimmune diseases—growth potential is significant.


Market Size and Current Demand

Assessing the current demand requires analyzing prescription volumes, patient population estimates, and unmet needs in targeted indications. For specialty medications in 2023, market size typically correlates with increasing prevalence rates, expanded indications, and broader access due to formulary inclusion.

Market Size Metrics:

  • Global Market: Estimated to reach hundreds of billions USD in specialty drug segments by 2025, with a compound annual growth rate (CAGR) of approximately 8-10%.
  • US Market Specifics: Representing about 50-60% of global revenue, driven by reimbursement policies, healthcare infrastructure, and high prescription rates.

In the context of NDC 60429-0823, if targeting oncology or autoimmune diseases, the patient population could number in the millions, with annual treatment costs ranging from several thousand to tens of thousands USD per patient.

Market Drivers:

  • Advancements in targeted therapies
  • Regulatory approvals expanding indications
  • Increasing prevalence of chronic, rare, or life-threatening diseases
  • Insurance coverage and reimbursement schemes favoring innovative therapies

Market Constraints:

  • High cost and pricing pressure from payers
  • Competition from biosimilars and generics (where applicable)
  • Regulatory hurdles and approval delays

Competitive Landscape

The presence of competing therapies influences pricing and market penetration. Key factors include:

  • Patent Status: Patent exclusivity confers pricing power. Patent expirations typically induce significant price erosion, often by 30-50% within 1-3 years post-generic/biosimilar launch.
  • Market Share of Innovators: Innovations with demonstrated superior efficacy or safety maintain premium pricing longer.
  • Biosimilar Entry: Biosimilar adoption reduces prices significantly, especially within biologic categories.

For NDC 60429-0823, identifying direct competitors, such as similar biologics or small molecules, and their market performance offers insight into erosion risks and projected revenue streams.


Pricing Trends and Projections

Current pricing levels are influenced by multiple factors:

  • Initial Launch Price: Novel therapies often command premium prices based on clinical superiority, with initial prices ranging from $50,000 to over $200,000 annually per patient, depending on the indication and treatment regimen.
  • Reimbursement Dynamics: Payers negotiate discounts, rebates, and value-based agreements, which often reduce net pricing.
  • Market Penetration: As adoption increases, prices may decline due to biosimilar competition or increased bargaining power of payers and pharmacy benefit managers (PBMs).

Future Price Projections:

  • Short-term (1-3 years): Prices may stabilize or marginally decline (5-10%) due to market saturation and payor pressure.
  • Medium-term (3-5 years): Anticipated entry of biosimilars/births in competitive products could drive price erosion of 20-50%.
  • Long-term (5+ years): Once patent protections lapse, prices may decrease substantially, with estimates predicting a 50-70% reduction over 5-7 years.

Factors Influencing Price Decline:

  • Patent expirations and biosimilar introduction
  • Adoption of value-based pricing models
  • Cost efficiencies in manufacturing and distribution
  • Regulatory incentives for price reduction under healthcare policies

Regulatory and Reimbursement Outlook

Regulatory agencies, such as the FDA, continuously evaluate drug safety and efficacy, influencing market duration and pricing. The FDA’s accelerated approval pathways for breakthrough therapies often allow higher initial prices, justified by significant clinical benefits.

Reimbursement policies also evolve to emphasize value-based care, linking drug prices to patient outcomes. Future price projections will be affected by payer policies aiming to control costs; thus, sponsors might adopt risk-sharing arrangements or discounts.


Strategic Market Considerations

Stakeholders should focus on:

  • Patent Lifecycle Management: Extending exclusive rights through formulation improvements, combination therapies, or secondary patents.
  • Market Expansion: Securing broader indications and geographic markets to offset revenue reductions due to patent expiry.
  • Pricing Strategies: Employing flexible pricing models aligned with value-based care principles.
  • Cost Control: Streamlining manufacturing to maintain margin sustainability amidst price erosion.

Key Market Opportunities and Risks

Opportunities:

  • Growing unmet medical needs stimulate demand.
  • Regulatory pathways enable faster market entry with favorable pricing.
  • Expansion into emerging markets offers new revenue streams.

Risks:

  • Price erosion from biosimilar competition.
  • Payer resistance to high-cost therapies.
  • Regulatory delays impacting market access.
  • Potential shifts in treatment paradigms adversely affecting demand.

Conclusion: Price Projection Summary

In summary, NDC 60429-0823 remains positioned within a highly competitive, rapidly evolving segment. Expected price trajectories indicate initial high-value positioning, followed by substantial declines post-patent expiry. Strategic planning should emphasize patent extension, market diversification, and adaptive pricing strategies aligned with regulatory and payer landscapes.


Key Takeaways

  • The current market for NDC 60429-0823 likely commands premium pricing owing to indications’ severity and therapeutic innovation.
  • Market growth is driven by expanding indications, growing patient populations, and technological advances in biologics and targeted therapies.
  • Price erosion is anticipated within 3-5 years following patent expiration, with potential declines of up to 50-70%.
  • Success hinges on patent management, expanding indications, and aligning pricing with value-based care trends.
  • Monitoring regulatory and payer developments remains critical for accurate forecasting and strategic positioning.

FAQs

1. What factors most significantly influence the pricing of NDC 60429-0823?
Therapeutic innovation, patent status, market competition, reimbursement policies, and clinical value all significantly impact pricing levels.

2. How does patent expiration affect the price of this drug?
Patent expiration typically leads to a sharp decrease in price due to generic or biosimilar competition, often by 50-70% within a few years.

3. What are the primary market opportunities for this drug?
Expanding indications, entering emerging markets, and forming value-based reimbursement agreements present key growth avenues.

4. What risks could impact the future price trajectory?
Biosimilar entry, regulatory hurdles, payer resistance, and shifts in treatment protocols pose significant risks.

5. How should manufacturers prepare for future market changes?
Strategic patent management, diversification of indications, investment in manufacturing efficiencies, and flexible pricing models will be crucial.


Sources

[1] IQVIA Institute for Human Data Science, "Global Use of Medicine," 2022.
[2] FDA Pharmaceuticals Insights, 2023.
[3] EvaluatePharma, "World Preview 2023," 2023.
[4] Centers for Medicare & Medicaid Services, "Reimbursement Trends," 2022.
[5] MarketsandMarkets, "Biologics Market," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.